Cancer Family
Mast Cell Neoplasm
CI-CAN-00000257Explore in graph →
HematologicNon-malignant9 active trials2 approved drugs4 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000257Explore in graph →
Clinical trials
101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | active not recruiting | Phase 1 | 130 | MacroGenicsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06327685 | Avapritinib With Decitabine in Patients With SM-AHN | recruiting | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04681105 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies |
| completed |
| Phase 1 |
| 13 |
| City of Hope Medical CenterOTHER |
| 1 |
| Jan 28, 2026 |
| clinicaltrials |
| NCT05609942 | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies(AZURE) | terminated | Phase 1 | 9 | Blueprint Medicines CorporationINDUSTRY | 7 | Apr 10, 2025 | clinicaltrials |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | completed | Phase 1 | 282 | Deciphera Pharmaceuticals, LLCINDUSTRY | 6 | Dec 13, 2023 | clinicaltrials |
| NCT02561988 | (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | completed | Phase 1 | 86 | Blueprint Medicines CorporationINDUSTRY | 2 | Mar 17, 2023 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT02808793 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 | completed | Phase 1 | 25 | Allakos Inc.INDUSTRY | 1 | Mar 13, 2019 | clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Jul 28, 2026source: clinicaltrials